While PI3K-AKT signalling plays a critical role in breast cancer, a complex network of genetic alterations, and secondary or complimentary signalling and regulatory mechanisms that control pathway activity also influence benefit to different PI3K therapeutic approaches targeting this pathway9,10. This evidence concerns the gene PIK3CA and breast carcinoma.